Lupin Launches Authorized Generic Version of PENNSAID® 2% w/w in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of authorized generic version of PENNSAID® (Diclofenac Sodium Topical Solution), 2% w/w of Horizon Pharma Therapeutics.

Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID®) had estimated annual sales of USD 509 million in the U.S. (IQVIA MAT October 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 754.55 as compared to the previous close of Rs. 769.75. The total number of shares traded during the day was 16017 in over 1161 trades.

The stock hit an intraday high of Rs. 772.50 and intraday low of 752.90. The net turnover during the day was Rs. 12167643.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals PENNSAID DiclofenacSodiumTopicalSolution HorizonPharmaTherapeutics